10-Q: Tharimmune Reports Q1 2025 Financial Results, Prioritizes Opioid Prophylaxis Program

Tharimmune, a clinical-stage biotechnology company, announced its Q1 2025 financial results, highlighting a net loss of $2.54 million and a strategic shift towards prioritizing its TH104 program for opioid prophylaxis.

Summary

• Tharimmune, Inc. reported a net loss of $2.54 million for the three months ended March 31, 2025, compared to a net loss of $2.26 million for the same period in 2024.
• Research and development expenses decreased to $0.59 million from $1.03 million year-over-year, primarily due to reduced clinical trial and preclinical vendor expenses.
• General and administrative expenses increased to $1.95 million from $1.32 million year-over-year, driven by higher investor relations, corporate taxes, and intellectual property expenses.
• The company is shifting its focus to TH104 for temporary prophylaxis of respiratory and/or nervous system depression in military personnel and chemical incident responders entering an area contaminated with high-potency opioids (PrHPO).
• The FDA provided positive feedback on the PrHPO indication, suggesting a 505(b)(2) NDA pathway may be possible without additional clinical trials.
• Tharimmune is delaying the Phase 2 trial for TH104 in moderate-to-severe chronic pruritus in PBC patients until after planning and completing a hepatic impairment study.
• The company had cash of $1.08 million as of March 31, 2025, compared to $3.56 million as of December 31, 2024.
• The company has raised $0.3 million through an at-the-market offering agreement (ATM Agreement) and $3.6 million through private placement offerings.
• The company expresses substantial doubt about its ability to continue as a going concern for at least one year.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there's positive feedback from the FDA regarding the opioid prophylaxis program, the company's financial situation is concerning, with a significant net loss, decreased cash reserves, and doubts about its ability to continue as a going concern. The delay in the Phase 2 trial for PBC patients is also a negative factor.

Positives

• The FDA provided positive feedback on the TH104 program for opioid prophylaxis, potentially allowing for a faster regulatory pathway.
• The company has identified a lead program (PrHPO) that may not require additional clinical trials before NDA submission.
• The company is actively progressing its Chemistry, Manufacturing, and Controls (CMC) plan to meet the stringent requirements for filing an NDA with the FDA.
• Phase 1 clinical trial with TH104 showed consistent pharmacokinetic (PK) profiles across buccal and intravenous routes of administration with a comparable safety and tolerability profile between routes of administration.

Negatives

• The company reported a net loss of $2.54 million for Q1 2025.
• The company's cash reserves decreased significantly from $3.56 million at the end of 2024 to $1.08 million as of March 31, 2025.
• The company expresses substantial doubt about its ability to continue as a going concern.
• The Phase 2 trial for TH104 in PBC patients is being delayed.

Risks

• The company's ability to continue as a going concern is uncertain, requiring substantial additional funding.
• The company's success depends on obtaining regulatory approvals and successfully commercializing its product candidates.
• The company faces risks related to clinical trial outcomes, dependence on third parties, and intellectual property protection.
• The company is subject to risks common to biopharmaceutical and biotechnology companies including, but not limited to, the development of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, product liability, uncertainty of market acceptance of products and the need to obtain additional financing.

Future Outlook

The company is prioritizing the development of TH104 for opioid prophylaxis (PrHPO) and plans to file a 505(b)(2) NDA. The company will delay the Phase 2 trial for TH104 in PBC patients until after planning and completing a hepatic impairment study. The company will need substantial additional funding to support future operating activities and expresses substantial doubt about its ability to continue as a going concern.

Industry Context

The company is operating in the competitive biotechnology industry, focusing on immunology, inflammation, and oncology. The shift in focus to TH104 for opioid prophylaxis reflects a strategic response to regulatory feedback and market opportunities. The company's success depends on its ability to navigate the regulatory landscape, secure funding, and achieve clinical milestones.

Comparison to Industry Standards

• It is difficult to compare Tharimmune's results to industry standards without specific financial benchmarks for similar-stage biotechnology companies.
• Many comparable companies are private and do not release financial information.
• However, the company's cash burn rate and need for additional funding are common challenges for early-stage biotech firms.
• The shift in focus to TH104 for opioid prophylaxis is a strategic move that could potentially accelerate the regulatory pathway and reduce development costs, which would be a positive differentiator compared to companies pursuing more traditional drug development strategies.

Stakeholder Impact

• Shareholders face increased risk due to the company's financial instability and need for additional funding.
• Employees may experience uncertainty due to the company's financial challenges.
• Patients may experience delays in the development of treatments for PBC and other conditions.
• Suppliers and creditors face increased risk of non-payment.

Next Steps

• Develop TH104 as a transmucosal buccal film product for temporary prophylaxis of respiratory and/or nervous system depression in military personnel and chemical incident responders entering and area contaminated with high-potency opioids.
• Develop TH104 as a transmucosal buccal film product for the treatment of moderate-to-severe chronic pruritus in PBC and other inflammatory diseases.
• Develop TH023 by obtaining regulatory authorization to initiate a first-in-human bioavailability clinical trial and pursue an IND through the FDA post optimizing its CMC program.
• Create a preclinical and clinical path forward for, HS1940, a unique PD-1 knob-domain antibody fragment as a bispecific biologic against VEGF with unique binding differentiation for IO vulnerable tumors.
• Continue to advance pre-clinical candidate selection activities against HER2/HER3 receptors with various antibody formats, including HS3215 designed for multiple solid tumor types.
• Hasten the discovery of next generation multi-specific (biand tri) antibodies with binding capabilities to novel epitopes of combinations of HER2 and HER3 with and without toxin delivery capacity to multiple high unmet need rare cancers and other validated immunology and metabolic targets.
• Pursue strategic collaboration opportunities including partnering and potential merger and acquisition transactions to maximize the value of our pipeline to bring novel therapies to patients suffering from high unmet need conditions

Key Dates

Keywords

TH104, PrHPO, opioid prophylaxis, clinical trial, FDA, financial results, biotechnology, research and development, net loss, going concern, Tharimmune